ATE234631T1 - Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten - Google Patents

Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten

Info

Publication number
ATE234631T1
ATE234631T1 AT97930276T AT97930276T ATE234631T1 AT E234631 T1 ATE234631 T1 AT E234631T1 AT 97930276 T AT97930276 T AT 97930276T AT 97930276 T AT97930276 T AT 97930276T AT E234631 T1 ATE234631 T1 AT E234631T1
Authority
AT
Austria
Prior art keywords
rsv
piv
viruses
pyramyxoviridae
preparation
Prior art date
Application number
AT97930276T
Other languages
English (en)
Inventor
Michel H Klein
George A Cates
Mary E Ewasyshyn
M Louise Herlocher
H F Maassab
Original Assignee
Aventis Pasteur
Univ Michigan
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Aventis Pasteur, Univ Michigan filed Critical Aventis Pasteur
Application granted granted Critical
Publication of ATE234631T1 publication Critical patent/ATE234631T1/de

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A61K2039/541—Mucosal route
    • A61K2039/543—Mucosal route intranasal
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pulmonology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
AT97930276T 1996-07-12 1997-07-11 Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten ATE234631T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67920696A 1996-07-12 1996-07-12
PCT/CA1997/000499 WO1998002180A1 (en) 1996-07-12 1997-07-11 Two-step immunization procedure against the pyramyxoviridae family of viruses using attenuated viral strains and subunit protein preparation

Publications (1)

Publication Number Publication Date
ATE234631T1 true ATE234631T1 (de) 2003-04-15

Family

ID=24725990

Family Applications (1)

Application Number Title Priority Date Filing Date
AT97930276T ATE234631T1 (de) 1996-07-12 1997-07-11 Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten

Country Status (7)

Country Link
US (1) US20030049276A1 (de)
EP (1) EP0936921B1 (de)
AT (1) ATE234631T1 (de)
AU (1) AU3431397A (de)
CA (1) CA2260107A1 (de)
DE (1) DE69720024D1 (de)
WO (1) WO1998002180A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6077514A (en) * 1996-04-04 2000-06-20 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
WO1997038138A1 (en) * 1996-04-04 1997-10-16 The Regents Of The University Of Michigan Attenuated respiratory syncytial virus
AU731777B2 (en) 1998-11-30 2001-04-05 Nihon Nohyaku Co., Ltd. Aniline derivative and process for producing the same
DE60016953T3 (de) * 1999-10-22 2008-05-15 Archus Orthopedics Inc., Redmond Facettenarthroplastiegeräte
US7371392B2 (en) 2000-02-02 2008-05-13 The United States Of America As Represented By The Department Of Health And Human Services Cd40 ligand adjuvant for respiratory syncytial virus
DK1409014T3 (da) * 2001-12-20 2007-07-30 Sanofi Pasteur Ltd Immunogene sammensætninger, der omfatter et antigen og et oprenset M-protein fra respiratorisk syncytial virus
EP2516623B1 (de) * 2009-12-23 2016-10-05 Sanofi Pasteur Methode zur kultivierung von adhärenten zellen zu mikrocarrier

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1987004185A1 (en) * 1986-01-14 1987-07-16 University Of North Carolina Vaccines for human respiratory virus
IL105456A (en) * 1992-04-21 1996-12-05 American Home Prod Vaccines of attenuated respiratory syncytial virus
AU676340B2 (en) * 1993-05-25 1997-03-06 Wyeth Holdings Corporation Adjuvants for vaccines against respiratory syncytial virus

Also Published As

Publication number Publication date
DE69720024D1 (de) 2003-04-24
EP0936921A1 (de) 1999-08-25
AU3431397A (en) 1998-02-09
WO1998002180A1 (en) 1998-01-22
EP0936921B1 (de) 2003-03-19
CA2260107A1 (en) 1998-01-22
US20030049276A1 (en) 2003-03-13

Similar Documents

Publication Publication Date Title
DK1296711T3 (da) HPV-E7 til behandling af humant papillomavirus
WO2001068116A3 (en) Immunostimulatory polynucleotide sequences for use in preventing and treating respiratory viral infections
RU94042722A (ru) Химерный белок, ген, клетка, вектор, способ получения химерного белка, вакцина
CA2311492A1 (en) Vaccines with an ltb adjuvant
DK0830141T3 (da) Forbedrede virusvacciner
DE60226911D1 (de) Entwicklung einer Vakzine zur Prävention von Infektionen mit Filovirus bei Primaten
AU2684792A (en) Porcine reproductive respiratory syndrome vaccine and diagnostic
WO2005116270A3 (en) Influenza virus vaccine composition and method of use
ZA964694B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline immunodeficiency virus infection.
DK1216053T3 (da) Influenzavaccine
FI905184A0 (fi) Kimeriska glykoproteiner som innehaoller immunogeniska delar av human parainfluensa-virus typ 3.
TW377373B (en) Recombinant raccoon pox viruses and their use as an effective vaccine against feline infectious peritonitis virus disease
ATE234631T1 (de) Immunisierungsverfahren in zwei schritten gegen pyramyxoviridae-viren unter verwendung abgeschwächter viraler stämme und preparation von proteinuntereinheiten
DE69716741D1 (de) Pharmazeutische zusammensetzung, enthaltend serum-amyloid p-komponenten, zur prophylaxe und therapie von viralen infektionen sowie kit zur detektionvon komplexen zwischen solchen zusammensetzungen und viralen komponenten
IT1252687B (it) Vaccino di poxvirus ricombinante del virus del morbillo
UA84667C2 (ru) Вакцина, направленная против инфекции, вызванной вирусом герпеса болезни марека
JP2000512263A (ja) インフルエンザワクチン
EP1057889A4 (de) Verbessertes immunogen für inaktivierten impfstoff gegen infektion mit japanischen encephalitis viren und verfahren zu dessen herstellung
DK0833903T3 (da) Multivalent vaccine mod bovint coronavirus og fremgangsmåde til behandling af infektioner forårsaget af bovint coronavirus
DE69633919D1 (de) Mehrzweckvakzine gegen umhüllte viren
BR9909076A (pt) Vìrus atenuado do sarampo, recombinantemente gerado, isolado, vìrus do sarampo, vìrus sincicial respiratório humano (rsv), subgrupo b, atenuado, recombinantemente gerado, isolado, o rsv, subgrupo b, vacina processo para imunização de um indivìduo para induzir proteção contra vìrus do sarampo, processo para imunização de um indivìduo para induzir proteção contra o rsv, subgrupo b, composição, processo para produção de vìrus do sarampo infeccioso atenuado, processo para produção de rsv infeccioso atenuado subgrupo b
ES2162862T3 (es) Uso de la timosina para tratar la hepatitis c en pacientes que no responden al tratamiento con interferon.
KINOSHITA Studies on Inactivation of Rickettsia tsutsugamushi by Ultra-violet Irradiation I. Inactivation of Rickettsia tsutsugamushi by Ultra-violet Irradiation
DE60238554D1 (de) Vakzine gegen infektionskrankheiten
RU97107302A (ru) Способ иммунизации против инфекции, вызываемой вирусом клещевого энцефалита

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties